Related Articles
Isoquercitrin inhibits the progression of pancreatic cancer in vivo and in vitro by regulating opioid receptors and the mitogen-activated protein kinase signalling pathway Retraction in /10.3892/or.2023.8505
Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways Retraction in /10.3892/or.2023.8684
[Retracted] Isoquercitrin inhibits the progression of pancreatic cancer in vivo and in vitro by regulating opioid receptors and the mitogen‑activated protein kinase signalling pathway
[Retracted] Isoquercitrin inhibits the progression of liver cancer <em>in vivo</em> and <em>in vitro</em> via the MAPK signalling pathway
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer